Amendments to the Claims

Please cancel claims 13, 15, 17, 19, 21, 23-24, 47-58 and 60 without prejudice or disclaimer.

The following listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Previously amended) A method of treating psoriasis in a mammal comprising administering a VEGF antagonist to the mammal wherein the VEGF antagonist is selected from the group consisting of

acetylated Flt-1(1-3)-Fc,

Flt-1(1-$3_{R->N}$)-Fc,

Flt-1(1-$3_{\Delta B}$)-Fc,

Flt-1(2-$3_{\Delta B}$)-Fc,

Flt-1(2-3)-Fc,

Flt-1D2-VEGFR3D3-FcΔC1(a),

Flt-1D2-Flk-1D3-FcΔC1(a), and

VEGFR1R2-FcΔC1(a), such that psoriasis is treated.

Claims 2-4. (Canceled)

Claim 5. (Currently amended) The method of claim 1, wherein treating psoriasis results in reducing a symptom associated with psoriasis ~~the severity of a psoriatic lesion~~.

Claims 6-8. (Canceled)

Claim 9. (Currently amended) The method of claim ~~1~~ 5, wherein ~~treating psoriasis results in minimizing the extent of~~ the symptom associated with psoriasis is one or more of: a psoriatic lesion,

keratinocyte hyperproliferation, ~~hyperproliferation of keratinocytes associated with psoriasis,~~ epidermal hyperplasia, parakeratosis, microabcess, and rete ridge formation

Claims 10-24. (Canceled)

Claim 25. (Previously amended) The method of claim 1, wherein the administration is topical administration.

Claim 26. (Previously amended) The method of claim 1, wherein the administration is subcutaneous administration.

Claim 27. (Previously amended) The method of claim 1, wherein the administration is intramuscular, intranasal, intrathecal, intraarterial, intravenous, transvaginal, transdermal, or transanal administration.

Claims 28-30. (Canceled)

Claim 31 (withdrawn) A method of enhancing wound healing in a human comprising administering a VEGF antagonist to the human.

Claim 32 (withdrawn) A method of enhancing wound healing in a human comprising administering VEGFR1R2-FcΔC1(a) to the human.

Claim 33 (withdrawn) The method of any one of claims 31 or 32 wherein the administration is topical administration.

Claim 34 (withdrawn) The method of any one of claims 31 or 32 wherein the administration is subcutaneous administration.

Claim 35. (withdrawn) The method of any one of claims 31 or 32 wherein the administration is intramuscular, intranasal, intrathecal, intraarterial, intravenous, transvaginal, transdermal, or transanal administration.

Claim 36 (withdrawn) The use of a VEGF antagonist to enhance wound healing in a human.

Claim 37 (withdrawn) The use of VEGFR1R2-FcΔC1(a) to enhance wound healing in a human.

Claim 38. (Previously added) The method of claim 1, wherein the acetylated Flt-1(1-3)-Fc is acetylated with at least about a 10 fold molar excess to about a 100 fold molar excess of acetylation reagent.

Claim 39. (Previously added) The method of claim 1, wherein the Fc is the Fc of IgG.

Claim 40. (Previously added) The method of claim 1, wherein the VEGF antagonist is optionally pegylated.

Claim 41. (Previously added) The method of claim 40, wherein the pegylation is with 10K or 20K PEG.

Claim 42. (Previously added) The method of claim 40, wherein the pegylation is with 10K PEG.

Claim 43. (Previously added) The method of claim 40, wherein the pegylation is with 20K PEG.

Claim 44. (Previously added) The method of claim 1, wherein the Flt-1D2 component (1), the VEGFR3D3 component (2), and the FcΔC1(a) component (3) of the VEGF antagonist Flt-1D2-VEGFR3D3-FcΔC1(a) are arranged in an order selected from the group consisting of:

(1) (2) (3),

(1) (3) (2),

(2) (1) (3),

(2) (3) (1),

(3) (1) (2), and

(3) (2) (1).

Claim 45. (Previously added) The method of claim 1, wherein the Flt-1D2 component (1), the Flk-1D3 component (2), and the FcΔC1(a) component (3) of the VEGF antagonist Flt-1D2-Flk-1D3-FcΔC1(a) are arranged in an order selected from the group consisting of:

(1) (2) (3),

(1) (3) (2),

(2) (1) (3),

(2) (3) (1),

(3) (1) (2), and

(3) (2) (1).

Claim 46. (Previously added) The method of claim 1, wherein VEGFR1 component (1), the R2 component (2), and the FcΔC1(a) component (3) of the VEGF antagonist VEGFR1R2-FcΔC1(a) are arranged in an order selected from the group consisting of:

(1) (2) (3),

(1) (3) (2),

(2) (1) (3),

(2) (3) (1),

(3) (1) (2), and

(3) (2) (1).

Claims 47- 58. Canceled

Claim 59. (Previously added) The method of claim 1, wherein the mammal is human.

Claim 60. Canceled.